{"links":{"html":"https://www.erudio.com/reports/nest3-nct07595874","json":"https://www.erudio.com/reports/nest3-nct07595874.json","markdown":"https://www.erudio.com/reports/nest3-nct07595874.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"nest3-07595874"}},"request":"https://www.erudio.com/contact?report=nest3-07595874"},"offer":{"cited_commentary_sources":23,"verified_hcp_statements":127,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":10,"optional":true,"price_per_verified_person_usd":15,"price_usd":150,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"nest3-nct07595874"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=nest3-07595874","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/nest3-nct07595874","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T03:45:27.994774Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: per-finding counts. The trial's registration date is now stated."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":14,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Two-year disease-free survival rate"},{"claim_count":28,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":12,"title":"Secondary endpoints"},{"claim_count":21,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":24,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":13,"title":"Design and conduct"},{"claim_count":23,"coverage":"discussed","id":"A1","source_count":15,"title":"Earlier NEST immune remodeling and NEST3 predictive-marker research"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":3,"title":"CT staging, central review and possible overtreatment"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":2,"title":"Pathological-response interpretation and CRC ctDNA/MRD surrogacy"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":8,"title":"Referral, research access, affordability and geographic opportunity"},{"claim_count":26,"coverage":"discussed","id":"A5","source_count":12,"title":"Earlier-study lineage, funding and the neoadjuvant development pathway"},{"claim_count":21,"coverage":"discussed","id":"A6","source_count":10,"title":"Earlier NEST reception and patient-information expectations"}],"counts":{"cited_sources":24,"claims_by_expression_type":{"comparison":11,"experience":12,"interpretation":37,"opinion":35,"primary_context":1,"question":8,"restatement":13,"uncertainty":3,"unspecified":7},"claims_by_kind":{"protocol_statement":1,"source_observation":126},"clinician_statements":81,"evidence_units":95,"findings":9,"organisational_accounts":2,"people_cited":21,"people_identity_verified":10,"people_total":21,"screened_sources":35,"verified_claims":127},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":16,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":0,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":8,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"The threshold for practice change remains contested"},{"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":3,"questions":1,"restated":4,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":19},"ma_question":true,"named_voices":7,"passages":15,"sources":11,"sources_by_kind":{"commentary":10,"media":1}},"title":"Protecting curative surgery qualifies the enthusiasm for adding treatment"},{"id":"F3","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":1,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":7,"passages":13,"sources":7,"sources_by_kind":{"commentary":5,"media":1,"registry":1}},"title":"Durable cure matters more than pathological response alone"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":2,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":2,"passages":8,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"The preoperative interval is a research hypothesis, not an established optimum"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":0,"views":8},"has_counterview":false,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":2,"passages":6,"sources":3,"sources_by_kind":{"commentary":3}},"title":"CT-based selection attracts confident advocacy, with a specific and limited staging task"},{"id":"F6","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":4,"views":14},"has_counterview":true,"limitations":3,"links":{"context":2,"support":22},"ma_question":true,"named_voices":10,"passages":18,"sources":13,"sources_by_kind":{"commentary":12,"media":1}},"title":"Immune remodeling strengthens the activity rationale, but prediction remains unvalidated"},{"id":"F7","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"ctDNA/MRD is proposed as an early readout, with DFS still required"},{"id":"F8","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":10},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":6,"passages":14,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Research access depends on travel, geography and affordability"},{"id":"F9","structure":{"claims":21,"claims_by_group":{"comparisons":4,"experience":4,"questions":1,"restated":1,"views":11},"has_counterview":false,"limitations":3,"links":{"context":0,"support":22},"ma_question":true,"named_voices":7,"passages":15,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Development speed is linked to funding and an uncertain neoadjuvant approval path"}],"medical_affairs_question":"What improvement in durable cure, at what immune-toxicity and surgical cost, would justify adding BOT/BAL before curative surgery?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Enthusiasm has not settled what would justify changing practice"},{"id":"section-2","level":2,"title":"2. The additive strategy must not be mistaken for replacing curative treatment"},{"id":"section-3","level":2,"title":"3. Cure is the intended gain; response does not settle that gain"},{"id":"section-4","level":2,"title":"4. More time before surgery is being tested, not validated as better"},{"id":"section-5","level":2,"title":"5. Confidence in staging depends on the selection question being asked"},{"id":"section-6","level":2,"title":"6. Biological coherence supports investigation, not a ready-to-use predictor"},{"id":"section-7","level":2,"title":"7. MRD could accelerate learning, but the proposed pathway still ends with DFS"},{"id":"section-8","level":2,"title":"8. Interest in referral is conditional on realistic access"},{"id":"section-9","level":2,"title":"9. Faster development must still produce interpretable evidence"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":9},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":2}],"id":"T1","label":"Primary endpoint: Two-year disease-free survival rate"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":6},{"id":"F7","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":5},{"id":"F8","shared_claims":4}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":5},{"id":"F4","shared_claims":6},{"id":"F6","shared_claims":2},{"id":"F9","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":12},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":5},{"id":"F9","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":2},{"id":"F8","shared_claims":4},{"id":"F9","shared_claims":9}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T03:45:27.994774Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T05:47:44Z","record_hash":"509d67338693270c0d0285cbbe3491c7e55787f85ae1bc3b8bec023af191c60b","release_hash":"205e3db92f95dc3477d780078199eb4f920c83997023ddf4c9d60823971c492f","report_id":"erudio-nct07595874","run_id":"c4940435-cc61-443d-8a88-989fe00c7e08","schema_version":"5.0","slug":"nest3-07595874","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on NEST3 in the sources reviewed for this edition leads to one open question: What improvement in durable cure, at what immune-toxicity and surgical cost, would justify adding BOT/BAL before curative surgery? Its leading findings: (1) the threshold for practice change remains contested. (2) protecting curative surgery qualifies the enthusiasm for adding treatment. (3) durable cure matters more than pathological response alone. 6 more findings follow. 35 sources screened, 24 cited; not all HCPs or all public discussion.","meta_description":"35 sources screened · 127 verified statements (81 from clinicians verified by NPI or staff page) from 24 sources · 9 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T05:47:44Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T06:12:11Z","summary":"Corrected to match the delivered report: per-finding counts. The trial's registration date is now stated."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":35},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","41 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are selected public discussions, not a representative sample of HCP opinion. Reposts and relayed summaries do not constitute independent clinical observations or votes.","Some discussions explicitly labeled NEST-1 or NEST2 were not examined, although earlier-program experience could inform the same treatment decision.","No full NEST3 protocol, exact-trial results publication or exact product label was available among these sources. Earlier NEST activity must not be presented as NEST3 efficacy or an authorized-use determination.","The material mixes confirmed individual identities, unverified identities and authors whose clinical roles are not established. Source descriptions of credentials are not independently confirmed credentials.","Some episode remarks have no established speaker. They cannot be assigned to a named participant or counted as an additional person's agreement or disagreement.","Reported response and survival figures are commentary restatements with differing patient, tumor and cohort denominators. Pathological response is not established here as a validated survival surrogate.","Site availability, enrollment descriptions and plans reflect the time of the statements. Publication dates do not establish recording dates, study readout dates or changes of mind.","Detailed NEST3 toxicity grades, surgical morbidity, patient-level affordability and validated predictive-marker performance are not provided; their absence from these statements is not evidence of absence."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":5,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":17,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":23,"methods":1},"count":24,"evidence_window":{"end":"2026-10-01","start":"2026-08-26"},"retrieval_snapshot":"2026-10-29T02:57:22.059369Z","timeline":[{"count":11,"week":"2026-W35"},{"count":4,"week":"2026-W36"},{"count":6,"week":"2026-W38"},{"count":4,"week":"2026-W39"},{"count":2,"week":"2026-W40"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT07595874:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07595874:context","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7498381740282122240","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7499874239303544832","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7507098623566958592","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7507512483356561408","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7508013351973728256","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7508173241191129089","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7509617024105504768","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:88efaa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092615835068383675:2d9672c3-f54d-47b7-aeea-df9996a47e60","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092616900320583761:f5c798b7-1346-46f9-a091-744224e6a616","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092628951671722370:750b04ce-0222-49c8-9e01-040fb4f3689b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092652331632328813:00bde203-1789-467d-95dd-0e397649cd8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092859886602215676:14a72650-ee17-488d-97e7-c7d3c0008bd2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092915549965521062:ef37036e-bc28-4b81-8121-315e462e4910","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092948069419569513:f5311def-5603-4b97-a7d9-5edcd60de649","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092954041085051165:eab73c80-0fb0-4201-a146-59274ad3da4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092967361854710173:4fc7f097-3250-48f1-bf0b-1f20fadadfc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092975268713333078:5324cc26-b4fc-46c8-a159-66bb7080f10e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092992340809974005:a1c09d3b-7bd3-4cd0-8348-e7b41ec549c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093083011101470984:c601f290-09b2-467d-b4f4-77dc5e509d91","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093330937215942876:1412f38d-72d6-4ca8-af91-6f1e2728d60a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093332722131612122:d39c2d33-58b5-4c87-ac78-b2a31c3a4b88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093338223594676285:772774ea-cb42-453d-bed0-56a73022f72e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093360575166513454:54b36712-b0d7-4927-b6be-1b7b3368c089","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093722477243633935:fd42f879-8b40-4be1-93e1-473a17dd1ab6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096283891493675461:bdcac92d-96eb-45d7-9a30-2a151ca0fa32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098788677006905724:5d5176aa-bab7-49c6-8175-d84192dda9c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099616669572464742:9a6fb7d5-bc83-407e-a1f2-024147159150","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100636706646941953:51bc343d-efae-4e44-a009-d9240896f28e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101331480240853134:d5108692-e313-4eb4-ae19-fa0919751241","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101332291641614404:e065b01d-4ac9-4b46-acf8-75fcfdc1adc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101746533888831650:e3d226cc-6ea6-4fa1-93d7-5f1e8be95dd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103849129055305981:b8c99782-a736-4de8-8c3d-1a8974aa400c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105307781377208360:cf754081-6a6c-4993-a945-719b72655877","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105572549388283926:11f45929-3e3d-4f7a-8c01-398b253303fa","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":7,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":35},"count":35,"evidence_window":{"end":"2026-10-01","start":"2026-08-26"},"retrieval_snapshot":"2026-10-29T02:57:22.261244Z","timeline":[{"count":19,"week":"2026-W35"},{"count":4,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":7,"week":"2026-W38"},{"count":5,"week":"2026-W39"},{"count":3,"week":"2026-W40"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: balstilimab","status":"unmapped"},{"reason":"Unmapped registry intervention: botensilimab","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Advanced Colon Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Advanced Colorectal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Advanced Rectal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIB Colon Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIB Rectal Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIC Colon Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIC Rectal Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIA Colon Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIA Rectal Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIB Colon Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIB Rectal Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIC Colon Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IIIC Rectal Cancer AJCC v8","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"NEST3","aliases":["NEST3","Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)"],"brief_title":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","collaborators":["National Cancer Institute (NCI)"],"conditions":["Advanced Colon Adenocarcinoma","Advanced Colorectal Adenocarcinoma","Advanced Rectal Adenocarcinoma","Stage IIB Colon Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8"],"enrollment":{"count":100,"type":"ESTIMATED"},"interventions":[{"name":"Balstilimab","synonyms":["AGEN 2034","AGEN-2034","AGEN2034"],"type":"BIOLOGICAL"},{"name":"Biospecimen Collection","synonyms":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Botensilimab","synonyms":["AGEN 1181","AGEN-1181","AGEN1181","Anti-CTLA-4 Monoclonal Antibody AGEN1181"],"type":"BIOLOGICAL"},{"name":"Computed Tomography","synonyms":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","synonyms":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"}],"nct_id":"NCT07595874","official_title":"A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-12-16","type":"ESTIMATED"},"primary_endpoints":[{"description":"Defined as the percentage of patients that remain free from any signs of colon cancer at two years post-enrollment. Will be compared to the historical control rate of 76.8% (from the FoXTROT adjuvant chemotherapy arm) using a one-sided, one-sample log-rank test.","measure":"Two-year disease-free survival rate","timeFrame":"At 2 years post enrollment"}],"registered_date":{"date":"2026-05-19","type":"ACTUAL"},"registry_last_updated":"2026-10-19","registry_url":"https://clinicaltrials.gov/study/NCT07595874","short_name":"NEST3","short_name_basis":"registry_acronym","sponsor":"City of Hope Medical Center","start_date":{"date":"2026-07-01","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"25964","type":"sponsor_study_id"},{"id":"P30CA033572","type":"nih"},{"domain":"CTRP (Clinical Trial Reporting Program)","id":"NCI-2026-02923","type":"registry"}],"study_type":"INTERVENTIONAL"}}}